EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Shared evidence, different recommendations: a comparative analysis of Qdenga (TAK-003) dengue vaccine guidance for travellers across countries

Sarah L McGuinness iD, Dipti Patel, Helena H Askling, Camilla Rothe, Steven Schofield, Robert Steffen iD, Leo G Visser iD, Lin H Chen

Journal of Travel Medicine · 2026

DOI: 10.1093/jtm/taag065 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Travel Medicine, 2026. Verfasst von Sarah L McGuinness und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, VIC, 3004 Australia. Hauptthemen laut MEDLINE: Dengue, Dengue Vaccines, Travel, Vaccination. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dengue is an increasingly important cause of illness in travellers, and Qdenga (TAK-003) is the first dengue vaccine incorporated into guidance for travellers in multiple countries. However, clinicians and travellers may encounter differing recommendations across jurisdictions. This study compared guidance on the use of Qdenga in travellers across countries.

Methods

We conducted a comparative analysis of national guidance on Qdenga use for travellers across countries, using survey data and structured review of publicly available recommendations. Guidance was synthesized according to dengue immune status and mapped across recurring decision domains.

Results

Survey responses were obtained from 18 advisory bodies across 17 countries between March and April 2026, including 12 non-endemic countries where Qdenga was licensed and guidance published. Guidance was generally more restrictive than regulatory authorization. While there was broad agreement in recommending vaccination for travellers with laboratory-confirmed prior dengue infection, recommendations for those without documented infection varied widely. All advisory bodies considered destination-specific dengue risk but differed in whether and how they used travel duration, repeated or cumulative exposure, traveller characteristics and host susceptibility factors to determine vaccine eligibility. Some recommendations restricted vaccination to travellers with prior dengue infection, whereas others extended eligibility to selected travellers without documented prior infection or recommended vaccination based on exposure risk, irrespective of serostatus. Approaches also differed in assessment of prior dengue infection and whether completion of the two-dose series before travel was required.

Conclusions

Variation in Qdenga guidance reflects differences in how advisory bodies interpret shared evidence and manage uncertainty arising from data gaps and differences between trial populations and travellers. Additional data on vaccine effectiveness and clinical outcomes among seronegative travellers and older adults may help reduce uncertainty and support greater alignment of future recommendations. Regardless, transparency and shared clinical decision-making remain essential when discussing dengue vaccination with travellers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DengueDengue VaccinesTravelVaccinationTravel MedicineHumansPractice Guidelines as Topic

Stichwörter der Autor:innen

NITAGdecision-makingdengue vaccinesguidelinesrisk assessmentserologytravel vaccination

Substanzen

Dengue Vaccines

Autor:innen und Institutionen

  • School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Road, Melbourne, VIC, 3004 Australia.
  • Department of Infectious Diseases, The Alfred and School of Translational Medicine, Monash University, 55 Commercial Road, Melbourne, VIC 3004, Australia.
  • National Travel Health Network and Centre (NaTHNaC), University College London Hospitals, 250 Euston Road, London NW1 2PG, UK.
  • Department of Medicine, Division of Infectious Diseases, Karolinska Institutet, K2 Medicin, Solna 171 77 Stockholm, Sweden.
  • Academic Specialist Centre, Stockholm Health Care Services, Solnavägen 1E, 113 65 Stockholm, Sweden.
  • Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, 80802 Munich, Bavaria, Germany.

ORCID-Profile: Sarah L McGuinness, Robert Steffen, Leo G Visser

Förderung

  • National Health and Medical Research Council

Zitieren

APA

McGuinness, S. L., Patel, D., Askling, H. H., Rothe, C., Schofield, S., Steffen, R., Visser, L. G., & Chen, L. H. (2026). Shared evidence, different recommendations: a comparative analysis of Qdenga (TAK-003) dengue vaccine guidance for travellers across countries. Journal of Travel Medicine. https://doi.org/10.1093/jtm/taag065

Vancouver

McGuinness SL, Patel D, Askling HH, Rothe C, Schofield S, Steffen R, et al. Shared evidence, different recommendations: a comparative analysis of Qdenga (TAK-003) dengue vaccine guidance for travellers across countries. Journal of Travel Medicine. 2026. doi:10.1093/jtm/taag065

BibTeX
@article{McGuinness2026,
  author = {McGuinness, Sarah L and Patel, Dipti and Askling, Helena H and Rothe, Camilla and Schofield, Steven and Steffen, Robert and Visser, Leo G and Chen, Lin H},
  title = {Shared evidence, different recommendations: a comparative analysis of Qdenga (TAK-003) dengue vaccine guidance for travellers across countries},
  journal = {Journal of Travel Medicine},
  year = {2026},
  doi = {10.1093/jtm/taag065}
}
Kostenlos starten →